Aptamer Group Regulatory News (APTA)

5 April 2023

Aptamer Group plc

("Aptamer", the "Company" or the "Group")

Total Voting Rights

In compliance with the FCA's Disclosure Guidance and Transparency Rules (the "Rules"), the Company announces that, as at the date of this announcement, it has 69,091,717 ordinary shares of £0.001 each ("Ordinary Shares") in issue. The Company does not hold any shares in treasury and all of the Ordinary Shares have equal voting rights.

The figure of 69,091,717 Ordinary Shares represents the total voting rights in the Company and may be used by shareholders as the denominator for the calculations by which they can determine if they are required to notify their interest in, or a change to their interest in the Company under the Rules.

- ENDS -

For further information, please contact:

Aptamer Group plc

Dr Arron Tolley +44 (0) 1904 217 404

SPARK Advisory Partners Limited - Nominated Adviser  

Andrew Emmott / Adam Dawes +44 (0) 20 3368 3550

Liberum Capital Limited - Broker

Richard Lindley / Ben Cryer / Cara Murphy +44 (0) 20 3100 2000

Consilium Strategic Communications

Matthew Neal / Chris Welsh / Lucy Featherstone +44 (0) 20 3709 5700

aptamergroup@consilium-comms.com

About Aptamer Group plc

Aptamer Group develops custom affinity binders through its proprietary Optimer® platform to enable new approaches in therapeutics, diagnostics and research applications. The Company strives to deliver transformational solutions that meet the needs of life science researchers and developers through the use of its proprietary Optimer platform.

Optimer binders are oligonucleotide affinity ligands that can function as an antibody alternative. The global affinity ligand market is currently worth over $170.0 billion. Optimer binders are engineered to address many of the issues found with alternative affinity molecules, such as antibodies, and offer new, innovative solutions to bioprocessing, diagnostic and pharmaceutical scientists.

Aptamer Group has successfully delivered projects for global pharma companies, diagnostic development companies, and research institutes covering a range of targets and applications with the objective of establishing royalty-bearing licenses. Through the unique Optimer technology and processes, scientists and collaborators are enabled to make faster, more informed decisions that support discovery and development across the Life Sciences.